Continued research in the treatment of castration-resistant prostate cancer (CRPC) has allowed for a clearer understanding of this disease entity and further treatment advances.
In a study recently published by Beer et al. (1) in the New England Journal of Medicine, another advance to treatment was demonstrated for the androgen receptor (AR) signaling inhibitor, enzalutamide, in patients with chemotherapy-naïve metastatic CRPC. Although a large majority of patients responded favorably to enzalutamide in the prechemotherapy setting, a small but significant proportion of patients demonstrated no meaningful benefit to this agent. This highlights an important concept in the understanding of this disease: inherent and acquired resistance to AR-targeting therapies.
Written by:
Maughan BL, Antonarakis ES. Are you the author?
Prostate Cancer Research Program, Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Reference: Asian J Androl. 2014 Aug 15. Epub ahead of print.
doi: 10.4103/1008-682X.137680
PubMed Abstract
PMID: 25155108